HOME >> MEDICINE >> NEWS
Neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds

The timing of systemic therapy--chemotherapy or endocrine therapy--for breast cancer does not appear to affect survival or disease progression. However, women who receive systemic therapy and radiation therapy without surgery may be more likely to experience a recurrence of their cancer compared with women treated with chemotherapy later, according to a new study in the February 2 issue of the Journal of the National Cancer Institute.

Neoadjuvant--also called preoperative or primary--systemic therapy for breast cancer may result in local tumor regression or even in a complete tumor response and may lead to a more limited extent of surgery--from radical mastectomy to some type of breast-conserving surgery--without risking patient survival. For these reasons, interest in the use of neoadjuvant therapy has been increasing.

To investigate how the timing of systemic therapy affects breast cancer outcomes, John P.A. Ioannidis, M.D., of the University of Ioannina School of Medicine in Greece, and colleagues performed a meta-analysis of nine randomized trials that had included nearly 4,000 breast cancer patients. The patients had been treated with systemic therapy either before or after surgery and/or radiation therapy.

There was no difference between neoadjuvant and adjuvant systemic therapy in terms of death, disease progression, or distant disease recurrence. However, neoadjuvant therapy was associated with a 22% increased risk of loco-regional disease recurrence compared with adjuvant therapy. This risk was higher (53%) when radiation therapy was used without surgery.

"[T]his meta-analysis demonstrates the equivalence of neoadjuvant and adjuvant treatments for breast cancer in terms of survival, disease progression, and distant recurrence and shows that an increased risk of loco-regional disease recurrence is associated with neoadjuvant treatment, especially when primary systemic treatment is not accompanied by any surgical interve
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
1-Feb-2005


Page: 1 2

Related medicine news :

1. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
2. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
3. Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes
4. Study supports tailoring adjuvant therapy for early-stage breast cancer
5. Nordic collaboration gives new insights into adjuvant chemotherapy
6. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
7. A blood test may reveal systemic factors that relate to periodontal disease, especially in men
8. Important information to consider about non-systemic cholesterol lowering agents
9. Study shows patch therapy may be as effective as oral medications
10. Novel therapy tested in mice could chase away cat allergies
11. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a ... treatment and accepting new pediatric patients, with or without a referral. Dr. Cotey knows ... a better orthodontic outcome and experience. When patients receive early treatment, they may achieve ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium ... finalization of the company’s executive management team with prominent executives from both inside and ... Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty years ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of the ... is touted to be the next revolution in our fight against this complex disease. ... form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... 2014 - 2025" report to their offering. ... The global ... million by 2025. Increasing geriatric population prone to orthopedic diseases ... navigation systems over the forecast period. Osteoarthritis and osteoporosis are ...
(Date:3/29/2017)... WALNUT CREEK, Calif. , Mar 29, 2017 ... tissue-sparing, cervical-fusion technology, announced the addition of two ... Scott Lynch has joined the company to ... is assuming International leadership.  Together, Mr. Lynch and ... industry experience.  Mr. Lynch joins ...
Breaking Medicine Technology:
Cached News: